The α-receptor for platelet-derived growth factor confers bone-metastatic potential to prostate cancer cells by ligand- and dimerization-independent mechanisms

Cancer Research

Volumn 70, Issue 10, 2010, Pages 4195-4203

  Russell, Mike R ^a   Liu, Qingxin ^a   Lei, Hetian ^b   Kazlauskas, Andrius ^b   Fatatis, Alessandro ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR;

ADULT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; BONE METASTASIS; CANCER CELL; CELL SURVIVAL; CONTROLLED STUDY; DIMERIZATION; HUMAN; HUMAN CELL; LIGAND BINDING; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION;

ADOLESCENT; ADULT; ANIMALS; BLOTTING, WESTERN; BONE MARROW; BONE NEOPLASMS; DIMERIZATION; HUMANS; LIGANDS; MALE; MICE; MICE, NUDE; MIDDLE AGED; PHOSPHORYLATION; PROSTATIC NEOPLASMS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 77952850723     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-4712     Document Type: Article

References (36)

1. Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer 2002;2:389-396
2. Mohammad KS, Fournier PG, Guise TA, Chirgwin JM. Agents targeting prostate cancer bone metastasis. Anticancer Agents Med Chem 2009;9:1079-1088
3. Fidler I. Critical determinants of metastasis. Semin Cancer Biol 2002; 12:89-96.
4. Fidler I. The pathogenesis of cancer metastasis: the "seed and soil" hypothesis revisited. Nat Rev Cancer 2003;3:453-458
5. Chambers AF, Groom A, Macdonald I. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002;2:563-572 (Pubitemid 37328923)
6. Fehm T, Mueller V, Marches R, et al. Tumor cell dormancy: implications for the biology and treatment of breast cancer. APMIS 2008; 116:742-753
7. Horak CE, Lee JH, Marshall JC, et al. The role of metastasis suppressor genes in metastatic dormancy. APMIS 2008;116:586-601.
8. Bussard K, Gay C, Mastro A. The bone microenvironment in metastasis; what is special about bone? Cancer Metastasis Rev 2008;27: 41-55.
9. Buijs JT, van der Pluijm G. Osteotropic cancers: from primary tumor to bone. Cancer Lett 2009;273:177-193
10. Mundy G. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-593 (Pubitemid 37328925)
11. Dolloff N, Russell MR, Loizos N, Fatatis A. Human bone marrow activates the Akt pathway in metastatic prostate cells through transactivation of the α-platelet-derived growth factor receptor. Cancer Res 2007;67:555-562 (Pubitemid 46192192)
12. Dolloff N, Shulby S, Nelson A, et al. Bone-metastatic potential of human prostate cancer cells correlates with Akt/PKB activation by α platelet-derived growth factor receptor. Oncogene 2005;24: 6848-6854 (Pubitemid 41487044)
13. Russell M, Jamieson W, Dolloff N, Fatatis A. The α-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases fromprostate cancer cells. Oncogene 2009;28:412-421
14. Fudge K, Wang CY, Stearns ME. Immunohistochemistry analysis of platelet-derived growth factor A and B chains and platelet-derived growth factor α and β receptor expression in benign prostatic hyperplasias and Gleason-graded human prostate adenocarcinomas. Mod Pathol 1994;7:549-554
15. Hofer M, Fecko A, Shen R, et al. Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors. Neoplasia 2004;6:503-512 (Pubitemid 39411086)
16. Chott A, Sun Z, Morganstern D, et al. Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol 1999; 155:1271-1279 (Pubitemid 29488934)
17. George DJ. Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate. Urology 2002;60:115-21; discussion 122.
18. Carvalho I, Milanezi F, Martins A, et al. Overexpression of platelet-derived growth factor receptor α in breast cancer is associated with tumour progression. Breast Cancer Res 2005;7:R788-95.
19. Lei H, Kazlauskas A. Growth factors outside of the platelet-derived growth factor (PDGF) family employ reactive oxygen species/Src family kinases to activate PDGF receptor α and thereby promote proliferation and survival of cells. J Biol Chem 2009;284:6329-6336
20. Soroceanu L, Akhavan A, Cobbs CS. Platelet-derived growth factor-α receptor activation is required for human cytomegalovirus infection. Nature 2008;455:391-395
21. Wang M, Stearns ME. Isolation and characterization of PC-3 human prostatic tumor sublines which preferentially metastasize to select organs in S.C.I D. mice. Differentiation 1991;48:115-125
22. Lei H, Velez G, Hovland P, et al. Growth factors outside the PDGF family drive experimental PVR. Invest Ophthalmol Vis Sci 2009;50:3394-3403
23. Shulby SA, Dolloff N, Stearns M, et al. CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Res 2004;64:4693-4698 (Pubitemid 38924507)
24. Heldin CH, Ostman A, Rönnstrand L. Signal transduction via platelet-derived growth factor receptors. Biochim Biophys Acta 1998;1378: F79-113.
25. Kaighn ME, Narayan KS, Ohnuki Y, et al. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Investigative urology 1979;17:16-23. (Pubitemid 9239413)
26. Heldin CH. Structural and functional studies on platelet-derived growth factor. EMBO J 1992;11:4251-4259
27. Heldin CH, Ostman A. Ligand-induced dimerization of growth factor receptors: variations on the theme. Cytokine Growth Factor Rev 1996;7:3-10. (Pubitemid 27202661)
28. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999;79:1283-1316 (Pubitemid 29473317)
29. Loizos N, Xu Y, Huber J, et al. Targeting the platelet-derived growth factor receptor α with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target. Mol Cancer Ther 2005;4:369-379
30. Kazlauskas A, Cooper JA. Autophosphorylation of the PDGF receptor in the kinase insert region regulates interactions with cell proteins. Cell 1989;58:1121-1133 (Pubitemid 19238189)
31. Holekamp NM. The vitreous gel: more than meets the eye. Am J Ophthalmol 2010;149:32-36
32. Saito Y, Haendeler J, Hojo Y, et al. Receptor heterodimerization: essential mechanism for platelet-derived growth factor-induced epidermal growth factor receptor transactivation. Mol Cell Biol 2001;21:6387-6394 (Pubitemid 32927407)
33. Emaduddin M, Bicknell DC, Bodmer WF, Feller SM. Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells. Proc Natl Acad Sci U S A 2008;105:2358-2362 (Pubitemid 351520518)
34. Koga F, Xu W, Karpova TS, et al. Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation. Proc Natl Acad Sci U S A 2006;103:11318-11322 (Pubitemid 44156515)
35. Chan PC, Chen YL, Cheng CH, et al. Src phosphorylates Grb2-associated binder 1 upon hepatocyte growth factor stimulation. J Biol Chem 2003;278:44075-44082
36. Rosenkranz S, DeMali KA, Gelderloos JA, et al. Identification of the receptor-associated signaling enzymes that are required for platelet-derived growth factor-AA-dependent chemotaxis and DNA synthesis. J Biol Chem 1999;274:28335-28343 (Pubitemid 129504700)